文献速递骨软组织肉瘤与黑色素瘤

特瑞普利单抗对比达卡巴嗪一线治疗晚期肢端型黑色素瘤的3期随机临床试验

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2026-01-01

这项多中心、开放标签、阳性对照3期随机试验纳入256例晚期黑色素瘤患者(62.7%为肢端型),比较特瑞普利单抗与达卡巴嗪一线治疗的疗效与安全性。

要点

  • 特瑞普利单抗较达卡巴嗪显著改善晚期肢端型黑色素瘤一线无进展生存。
  • BICR评估的ORR分别为11.0%与8.6%,中位缓解持续时间分别为13.8与6.9个月。
  • ≥3级治疗相关不良事件发生率28.3%,常见为脂肪酶升高、贫血等。

核心结论

  • 在晚期黑色素瘤(以肢端型为主)一线治疗中,特瑞普利单抗较达卡巴嗪显著改善无进展生存且安全性可接受。

研究设计与样本

  • 多中心、开放标签、阳性对照3期随机临床试验,2018年1月22日至2023年7月12日入组,纳入256例晚期黑色素瘤患者。
  • 患者按1:1随机接受特瑞普利单抗240 mg每2周(最长2年)或达卡巴嗪1000 mg/m2每3周,直至疾病进展或不可耐受毒性。
  • 主要终点为盲法独立中心评审(BICR)按RECIST 1.1评估的无进展生存期(PFS)。

主要发现

  • 包括肢端亚型在内的多数预设亚组中观察到一致的PFS获益。
  • BICR评估的客观缓解率分别为11.0%(95%CI 6.2%-17.8%)与8.6%(95%CI 4.4%-14.9%)。
  • 中位缓解持续时间分别为13.8个月(95%CI 5.9-不可评估)与6.9个月(95%CI 3.8-不可评估)。
  • 特瑞普利单抗组≥3级治疗相关不良事件发生于36例(28.3%),最常见(≥3%)为脂肪酶升高11例(8.7%)、贫血5例(3.9%)、γ-谷氨酰转移酶升高4例(3.1%)、低钠血症4例(3.1%)、血甘油三酯升高4例(3.1%)。

关键数值与推荐

  • 入组标准为组织学确诊的III或IV期黑色素瘤且未接受过晚期黑色素瘤全身治疗。
  • 共分析256例患者,中位年龄58岁(范围18-85岁),女性113例(44.3%),男性142例(55.7%),肢端型160例(62.7%)。
  • 特瑞普利单抗组127例,达卡巴嗪组128例(1例因GCP违例被排除)。
  • 中位随访时间11.8个月(范围0.1-62.5个月)。

临床怎么用

  • 对于晚期肢端型黑色素瘤一线治疗,特瑞普利单抗可作为较达卡巴嗪更优的PD-1抑制剂选择。
  • 治疗期间需监测脂肪酶、贫血、γ-谷氨酰转移酶、血钠及血甘油三酯等≥3级不良事件。

局限性

  • 开放标签设计,非盲法可能影响部分主观终点评估。
  • 中位随访时间较短(11.8个月),长期生存获益尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Programmed cell death 1 (PD-1) inhibitors have been the standard first-line treatment for advanced melanoma; however, their clinical benefit in advanced melanoma predominantly of acral subtype remains unclear. OBJECTIVE: To evaluate the efficacy and safety of toripalimab (a PD-1 inhibitor) vs dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, positive-control phase 3 randomized clinical trial enrolled patients with advanced melanoma from January 22, 2018, to July 12, 2023. Eligible patients had histologically confirmed stage III or IV melanoma and no prior systemic therapy for advanced melanoma. Data were analyzed from September 23 to November 27, 2023. INTERVENTION: Patients were randomized (1:1) to receive toripalimab, 240 mg, every 2 weeks for up to 2 years, or dacarbazine, 1000 mg/m2, every 3 weeks until disease progression or intolerable toxic effects. Patients in the dacarbazine group were allowed to receive toripalimab after radiographic disease progression. MAIN OUTCOMES AND MEASURES: Progression-free survival (PFS) assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS: The analysis included 256 patients (median [range] age, 58 [18-85] years; 113 females [44.3%] and 142 males [55.7%]), among whom 160 participants (62.7%) had acral melanoma; 127 were randomized to receive toripalimab and 128 to dacarbazine (1 patient was excluded for Good Clinical Practice violation). The median (range) follow-up period was 11.8 (0.1-62.5) months. Toripalimab significantly reduced the risk of disease progression or death by 29.2% (hazard ratio, 0.71; 95% CI, 0.53-0.95; P = .02) compared with dacarbazine as assessed by BICR . Consistent PFS benefit was observed in most predefined subgroups, including patients with acral subtype. The BICR-assessed objective response rate of 11.0% (95% CI, 6.2%-17.8%) vs 8.6% (95% CI, 4.4%-14.9%), and the median duration of response of 13.8 (95% CI, 5.9-not evaluable) months vs 6.9 (95% CI, 3.8-not evaluable) months, respectively, also favored toripalimab over dacarbazine. Grade 3 or worse treatment-related adverse events occurred in 36 patients (28.3%) receiving toripalimab, with the most common (≥3%) being increased lipase (11 patients [8.7%]), anemia (5 patients [3.9%]), increased γ-glutamyltransferase (4 patients [3.1%]), hyponatremia (4 patients [3.1%]), and increased blood triglycerides (4 patients [3.1%]). CONCLUSIONS AND RELEVANCE: This phase 3 randomized clinical trial found that as a first-line treatment for advanced melanoma predominantly of acral subtype, toripalimab showed a significant PFS benefit over dacarbazine and an acceptable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03430297.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Sheng X, Huang G, Fang M, et al. Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 41481311. doi:10.1001/jamaoncol.2025.5751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。